Adverse events linked to compounded GLP-1s include redness, site swelling, pain, and a red lump at the injection site, according to the FDA
The increased number of effective obesity treatments, I think, has reduced the stigma against treating obesity a little bit more, in part because these trials have shown the other health benefits for treating obesity
Qu son los GLP-1
Batch: GF-GLUTA600-B241 Assay Content: 580 mg Purity: greater than 99.8 percent Identification by FTIR Spectrum: 1000 Identification by Retention Time: 0.985 Molecular Ion Mass Identification: 307 Da Bacterial Endotoxins: below 0.001 EU/mg Total Aerobic Microbial Count: 0 CFU/g Total Yeast and Mold Count: 0 CFU/g Independent elemental impurity analysis confirmed no detectable arsenic, cadmium, cobalt, lead, mercury, nickel or vanadium, with all measured concentrations remaining below the laboratory detection limit
Clinical trials are being developed to study GLP-1s in patients receiving ongoing cancer treatment, as well as in patients who do not have diabetes or obesity